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www.embomolmed.org EMBOLung cancer is the first cause of cancer mortality worldwide, and its early
detection is currently the main available strategy to improve disease prognosis.
While early diagnosis can be successfully achieved through tomography-based
population screenings in high-risk individuals, simple methodologies are needed
for effective cancer prevention programs. We developed a test, based on the
detection of 34 microRNAs (miRNAs) from serum, that could identify patients
with early stage non-small cell lung carcinomas (NSCLCs) in a population of
asymptomatic high-risk individuals with 80% accuracy. The signature could
assign disease probability accurately either in asymptomatic or symptomatic
patients, is able to distinguish between benign and malignant lesions, and to
capture the onset of the malignant disease in individual patients over time. Thus,
our test displays a number of features of clinical relevance that project its utility
in programs for the early detection of NSCLC.INTRODUCTION
Non-small cell lung carcinoma (NSCLC) is the first cause of
cancer mortality worldwide (Parkin et al, 2005), largely due to
the lack of effective tools for early diagnosis. Patients diagnosed
with early stage disease (stage I) have a reasonably favourable
prognosis (60–80% survival at 5 years, Jemal et al, 2008).
Unfortunately, only 20–25% of all NSCLCs are diagnosed earlyFoundation, At the
ria, Universita’ degli
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ropean Institute of
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: þ39 02 94375991;
Mol Med 3, 495–503(Greenlee et al, 2000; Porter & Spiro, 2000). Tobacco exposure is
the major risk factor for lung cancer (Peto et al, 1996). Even in
former smokers, the tobacco-associated risk remains high for a
long time (Jemal et al, 2009). Thus, effective tools for the early
detection of NSCLC, especially in high-risk individuals, are
critically needed.
Low dose spiral computed tomography (LD-CT) has been
tested in prospective observational trials and has proven to be
an effective detection method for small nodules (even <5mm)
as well as for the diagnosis of asymptomatic lung cancers, most
of which (67–85%) are at stage I (Henschke et al, 2006;
Pastorino et al, 2003; Swensen et al, 2003; Veronesi et al, 2008).
There is debate over whether annual LD-CT screening
reduces the number of diagnoses of advanced stage disease
(stages III–IV) and lung cancer deaths (Bach et al, 2007; Chien
& Chen, 2008; McMahon et al, 2008), and the possibility has
been raised that LD-CT screening may lead to over-diagnosis
and over-treatment of biologically indolent cancers, which
would rarely reach clinical relevance or pose a health hazard
for patients (Reich, 2008; Welch et al, 2007). However, the
effectiveness of LD-CT has recently been confirmed, as a large
randomized trial (The National Lung Screening Trial,
Aberle et al, 2011) was prematurely stopped on the basis that
‘the accumulated data now provide a statistically convincing 2011 EMBO Molecular Medicine 495
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496answer to the study’s primary question’ (http://www.
cancer.gov/newscenter/pressreleases/NLSTresultsRelease).
While early diagnosis is indeed an effective method to reduce
lung cancer deaths, concerns remain regarding the feasibility of
large-scale population screening by LD-CT: the technique is
cumbersome, it requires specialized health centres, and the
recruitment of at-risk individuals with no symptoms of disease is
difficult. Therefore, the development of diagnostic blood tests
becomes of paramount relevance for the execution of effective
population screenings. The detection of specific circulating
microRNAs (miRNAs) might serve this purpose. Indeed there is
evidence to support the idea that circulating miRNAs with
diagnostic potential exist for almost every type of malignant
(Lawrie, 2010; Skog et al, 2008; Tanaka et al, 2009) and non-
malignant disease (Laterza et al, 2009; Redell et al, 2010; Rong
et al, 2011; Wang et al, 2009; Zhang et al, 2010), including lung
cancer (Wittmann & Jack, 2010). Here, we describe a blood test,365
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Serum miRNAs in asymptomatic NSCLC patients and healthy
smokers
We took advantage of a large study (the COSMOS study,
Veronesi et al, 2008), in which 5203 high-risk individuals were
screened by annual LD-CT to detect lung cancer (Fig 1A, clinical
and pathological information for all patients in this study are
summarized in Table SI of Supporting Information). Ninety-
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(55 at baseline and 38 at annual screening). Sera—collected
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Fabrizio Bianchi et al.(Fig 1A). At the time of serum collection, all patients were
asymptomatic, and the detection of cancer was solely a
consequence of their enrolment in the observational project.
We selected control sera (matched for confounding factors, such
as gender, age, and smoking exposure) from 69 individuals
enrolled in the same study, in whom no cancer was found by
LD-CT during the entire study (healthy smokers, henceforth
‘normal’) (Fig 1A). Sera from the COSMOS study were divided
into two sets: a training set (39 normal subjects and 25 with
adenocarcinomas—AC) and a testing set (30 normal subjects,
22 AC and 12 squamous cell carcinomas—SCC) (Fig 1A, and
Table 1).
A total of 365 miRNA assays were employed in the study
(listed in Table SII of Supporting Information). A series of
calibration tests (schematized in Fig 1B and described in Fig S1
and Table SII of Supporting Information) were performed to
select a pool of 147miRNAs that were informative (seeMaterials
and Methods Section and Fig S1 for details) for the purpose of
our study. The levels of these 147 miRNAs were evaluated in
RNAs extracted from all the training/testing sera (and also from
all other sera used in this study). After miRNA profiling and
normalization (see Materials and Methods Section, Table SIII
and Fig S2 of Supporting Information), we used the training
set to derive a 34-miRNA signature capable of separating
tumour from normal sera (see Materials and Methods Section,
and Table SIV of Supporting Information). One-way hierarchical
clustering analysis showed that the 34-miRNA signature is
composed of two main groups of miRNA, showing increased or
decreased expression in tumour versus normal sera, respectively
(Fig S3 and Table SIV of Supporting Information). Importantly,
the trend of regulation in tumour versus normal of these two
groups of miRNAs was maintained between the training and
the testing set, thus confirming stability of the expression
profile (Fig S3).Table 1. Clinical characteristics of patients of the training and testing sets
Categories Training set
(N¼64)
Testing set
(N¼64)
Symptomatic set
(N¼ 36)
Tumour 25 34 36
Normal 39 30 0
Male 45 43 30
Female 19 21 6
Non-smokers 0 0 8
Age (years) 586 606 66 8
Pack-years 54 18 49 17 45 37
Tumour subtype
AC 25 22 23
SCC 0 12 13
Tumour Stage
IA 19 18 7
IB 2 4 9
II–IV 4 12 20
AC, adenocarcinoma; SCC, squamous cell carcinoma.
The clinical and pathological characteristics are reported for the training and
testing sets of patients. The average and relative standard deviation (SD) is
indicated for age (years) and smoking status (pack-years).
www.embomolmed.org EMBO Mol Med 3, 495–503A 34-miRNA model for NSCLC diagnosis in asymptomatic
high-risk individuals
We developed a multivariate risk predictor, using the weighted
linear combination of the 34 miRNA expression values (see
Materials and Methods Section and Table SI of Supporting
Information), to assign each patient to a high or low risk
category (with a cut-off score set at 3.235 during the training of
the classifier, which was performed on the training set). In the
training set, the risk algorithm displayed an accuracy of 78%
and an area under the curve (AUC) of 0.92 (Table 2, Fig 2A). The
predictor was remarkably stable when applied to the testing set,
displaying an accuracy of 80% and an AUC of 0.89 (Table 2,
Fig 2A). Importantly, the algorithm, which was derived on a
training set containing only ACs, performed well in both SCCs
and ACs in the testing set (AUC: 0.85 and 0.94 for AC and SCC,
respectively; Table 2, Fig 2A). In addition, fairly accurate
predictions could also be obtained by employing models
containing fewer miRNAs. As shown in Fig S5, a 5-miRNA
model displayed an AUC of 0.77 when applied to the testing set.
By increasing the number of miRNAs, the predictor became
increasingly more accurate, reaching an AUC of 0.89 when the
34-miRNA model was employed.
Finally, it is of note that, while our training set was
intentionally enriched in stage I patients (one of our main
goals was to develop a signature sensitive enough to detect also
early stage cancers, in which surgery is most effective), the
testing set contained a relevant proportion of more advanced
cancers (Table 1). In the testing set, the predictor performedwell
for cancers of all stages (I–IV), with an AUC of 0.89 for stage I
tumours and 0.88 for stage II–IV (Table 2, Fig 2A), arguing for its
ability to detect all stages of NSCLCs in asymptomatic patients.
Indeed, a sensitivity analysis showed that the 34-miRNA
signature remained a strong predictor of risk independently
of the subgroup of patients considered (Fig 2B). Finally, it is
worth mentioning that comparable results (in the above-
described and in all subsequent analyses) were obtained using
two different methods for data normalization (see Fig S4 of
Supporting Information).Table 2. Performance of the predictive model in various sets
Set AUC ACC
%
SEN
%
SPE
%
Training set (39 N, 25 AC) 0.92 78a 69a 84a
Testing set (30 N, 22AC, 12 SCC) 0.89 80 71 90
Testing set—AC only (30 N, 22 AC) 0.85 79 64 90
Testing set—SCC only (30 N, 12 SCC) 0.94 88 83 90
Testing set—stage I only (30 N, 22 T) 0.89 77 59 90
Testing set—stage II–IV only (30 N, 12 T) 0.88 90 92 90
Performances of the 34-miRNA predictor model. The area under curve (AUC,
from receiver operating characteristic curves, see Fig 2A) is shown together
with the overall accuracy (ACC), the sensitivity (SEN, the probability for a
tumour to be correctly predicted as ‘tumour’) and specificity (SPE, the
probability for a normal sample to be correctly predicted as ‘normal’).
aAccuracy, sensitivity and specificity in the training set are based on K-fold
(K¼ 5) cross-validation result of the DLDA classifier (see Materials and
Methods Section).
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Figure 2. The 34-miRNA diagnostic model.
A. Receiver operating characteristic (ROC) curves of
the 34-miRNA diagnostic model (curves are
presented in two separate panels solely for
reasons of clarity). Colour codes are as per the
‘legend’. TR, training set; TS, testing set; TS-AC,
testing set considering only ACs; TS-SCC, testing
set considering only SCCs; TS-Stage I, testing set
considering only stage I tumours; TS-Stage II–IV,
testing set considering all other tumour stages.
B. Forest plot showing the 34-miRNA model
prediction strength in the testing set (all,
30 normal and 34 tumours) stratified by available
clinical-pathological parameters. Triangles
represent the odds ratios; lines represent the
relative 95% confidence intervals (nominal
logistic regression). Age (years) and packs/year
(p/y) cut-offs were defined by the relative
averages in the 64 patients. p-Value were <0.01
in all analyses (two-tails Fisher’s exact test).
C. Risk of cancer based on the 34-miRNA risk model
in NSCLC patients (separately for ACs and SCCs)
from the testing set (left panel) and symptomatic
cases (right panel). Average risk scores
and p-value (ANOVA) are also shown.
498Additional clinical validations
We performed a series of analyses to further validate the 34-
miRNA predictor and to gain further insights into its potential
value in the clinical setting. Initially, we wanted to exclude the
possibility that the performance of our predictor could be linked
to some unknown ‘study bias’. Such a bias could be
hypothetically represented by the fact that tumours detected
by LD-CT might be intrinsically different from those that
present themselves symptomatically, or to other systematic
biases in the management of the individuals enrolled in the
COSMOS trial.
To address this issue, we employed pre-operative sera from
an independent cohort of symptomatic NSCLC patients, who
underwent surgery at the European Institute of Oncology across
a number of years as part of the routine clinical activity of the
Institute (the Symptomatic set, 23 AC and 13 SCC, Fig 1A and
Table 1). As a stringent control for the symptomatic set, we
screened pre-operative sera from patients harbouring benign 2011 EMBO Molecular Medicinepulmonary hamartomas (PHs, 15 sera, Fig 1A). When the 34-
miRNA predictor was applied to evaluate the risk in the
symptomatic set and in the PH set, it performed remarkably well
(Fig 2C). The average risk index of NSCLCs patients was
virtually indistinguishable, both for ACs and SCCs, between the
symptomatic set and the testing set of the COSMOS trial
(Symptomatic set: AC¼ 7.0, SCC¼ 13.6; COSMOS set: AC¼ 7.7,
SCC¼ 14.6; Fig 2C). In addition, the average risk index of
patients from the symptomatic set was clearly higher, in a
statistically significant manner, than that of PH-harbouring
patients (average risk score PHs¼1.9, AC¼ 7.0, SCC¼ 13.6,
p-value <0.01 and <0.001 between PHs and AC or SCC,
respectively, Fig 2C, right). Finally, the risks of normal
individuals from the testing set of the COSMOS trial and of
PH-harbouring patients were similar and the difference was not
statistically significant (Cosmos set Normal¼4.2, Sympto-
matic set PHs¼1.9, p¼ 0.328, Fig 2C, see also Fig S4 of
Supporting Information).EMBO Mol Med 3, 495–503 www.embomolmed.org
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Fabrizio Bianchi et al.We next took advantage of sera from a group of 33 patients,
who were detected at baseline LD-CT with benign lung nodules
and did not develop lung cancer during the entire period of the
study (nodules, Fig 1A). This provided us with the opportunity
to test whether our predictor could distinguish between benign
and frankly malignant lung disease in asymptomatic patients.R
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Figure 3. Performance of the 34-miRNA diagnostic model under various
conditions of clinical interest.
A. Risk index in patients with LD-CT detected benign nodules (NOD), or
normal individuals (N). Average risk scores and p-value (Welch’s t-test) are
also shown.
B. Risk index in patients before disease onset (BDO) and after the onset of
disease (AC, SCC). Average risk scores and p-value (one-tailed paired t-test)
are also shown.
C. Risk index in patients with breast cancer (BC) or benign breast nodules
(NOD). Average risk scores and p-value (Welch’s t-test) are also shown.
www.embomolmed.org EMBO Mol Med 3, 495–503We therefore compared the performance of the predictor in the
‘normal’ sera of the testing set and in the sera of patients with the
LD-CT-detected benign nodules. There were no significant
differences in the average risk of the normal and nodule
categories in spite of the fact that the 34-miRNA model and
the risk algorithm were derived by training on a dataset (the
training set) that did not include nodules (average risk score:
normal¼4.2, nodules, 2.3, p¼ 0.36; Fig 3A). Indeed, the
specificity of the predictor in scoring patients with benign
nodules as ‘normal’ was 79% (26 out of 33 samples), whereas in
normal high-risk volunteers it was 90% (27 out of 30 samples).
In the COSMOS trial, the percentage of screened individuals who
displayed non-calcified nodules was 53% (Veronesi et al, 2008).
Thus, we predict that the false positive rate of our test applied to
a population of high-risk individuals (which comprises both
normal individuals and those with benign nodules) would
be 16%.
Next, we analyzed a group of sera collected before the onset
of NSCLC (i.e. from patients who were negative at the screening
round but who developed lung cancer >1 year after). For 13 of
such cases, we had both the sera harvested before disease onset
(BDO) and the tumour sera that were already included in the
training or testing sets. When the risk predictor algorithm was
applied, it indicated a significantly increased average risk index
for sera collected after the onset of the disease (average risk
BDO,7.1; tumour, 10.4; p< 0.001, paired t-test; Fig 3B). Thus,
at least in the cases analyzed, the 34-miRNA model was capable
of detecting the conversion from a normal to a malignant state.
Finally, we tackled the question of the specificity of the 34-
miRNA predictor for NSCLC detection, as opposed to other types
of cancer, by screening sera from a cohort of 18 patients with
invasive ductal breast carcinoma and 10 with breast benign
nodules. In unsupervised hierarchical clustering, using all
147 miRNAs, the expression profile of these samples did not
showmajor differences with respect to all other sera used in this
study (Fig S2 of Supporting Information). When the 34-miRNA
risk predictor algorithm was applied, it could not discriminate
between breast tumours and benign breast nodules (p¼ 0.65;
Fig 3C).DISCUSSION
We have developed a serum test that can identify patients with
early stage NSCLC in asymptomatic high-risk individuals. The
test displays several characteristics that are desirable in a
clinical setting: (i) it can be performed on modest amounts of
serum (0.5–1ml) without any need for a pre-amplification step,
(ii) it is likely going to be considerably cheaper, easier and more
immediately implementable (particularly from the point of view
of patient accrual and compliance) than current screening
procedures, (iii) it assigns disease probability accurately in high-
risk asymptomatic individuals, (iv) it can also distinguish
malignant lesions from benign nodules that are frequently found
by LD-CT in high risk population, (v) it captures the onset of the
malignant disease in asymptomatic individuals. When applied
to a high-risk population screened by LD-CT, the most powerful 2011 EMBO Molecular Medicine 499
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500tool for early diagnosis available, our test showed an accuracy of
80% andwas remarkably stable between training and testing sets.
A number of signatures have been reported, which were
developed for the diagnosis of NSCLCs (Chen et al, 2008; Foss
et al, 2011; Heegaard et al, 2011; Hu et al, 2010; Shen et al,
2011). The majority of these signatures were obtained (and
validated to various degrees) on symptomatic lung cancers, and
it is not presently known whether they can be useful in the
diagnosis of asymptomatic patients, for the purpose of
diagnostic anticipation. A study by Boeri et al (2011), however,
was published while we were completing the present manu-
script, portraying a study design similar to ours. Among various
signatures, these authors identify a diagnostic signature, which
is conceptually comparable to ours in that it allows diagnosis in
asymptomatic subjects. Their diagnostic signature is composed
of 13 miRNAs, five of which overlap with our signature, with
concordant direction of variation (upregulated or downregu-
lated). Although there is a partial overlap between the two
signatures, which may suggest that the two studies capture the
core of circulating miRNA differences between normal and
cancer individuals, the majority of the miRNAs are different.
The reason for this difference is presently unclear. As observed
for cancer messenger RNA (mRNA) signatures derived from
similar studies, differences could be due to intrinsic genetic
heterogeneity between groups of patients. It is also to be noted
that Boeri et al performed their analyses in plasma, while we
analyzed sera, and that it is known that differences in the
analyte can have an impact on the results of studies of this
nature (Heegaard et al, 2011; Kroh et al, 2010; McDonald et al,
2011). Finally, the signatures could be different as the result of
their intrinsically different properties. Our signature was trained
on a high number of controls, and upon validation showed a
remarkable specificity both on normal subjects and benign lung
nodules. It will be interesting to determine whether the
signature of Boeri et al possesses similar features when tested
on a high number of screening relevant controls, such as benign
lung nodules, which are detected at high frequency in high-risk
populations by LD-CT scan (Veronesi et al, 2008). Specificity is a
relevant issue when developing a signature for diagnostic
anticipation in high-risk individuals, and it becomes even more
relevant in the case of benign nodules. Our signature seems also
specific for lung cancer when compared to another type of
cancer (i.e. breast cancer).
An important question relates to the tissue origin of the serum
miRNA of our signature. In principle these miRNAs can
originate from the tumour itself or from host responses to the
tumour. In the former case, an additional question is whether
the miRNAs of the signature play any role in the process of lung
tumourigenesis. Our data do not allow us to distinguishing
between these possibilities. However, it is interesting to note
that several members of our predictor are directly involved in
lung cancer. Members of the Let-7 family (let-7 a/b/e are present
in the predictor and are downregulated in our tested tumour
sera) are often downregulated in lung cancer with diagnostic
and prognostic value (Yanaihara et al, 2006). These miRNAs
regulate lung tumour growth in NSCLC cell lines and mouse
models (Trang et al, 2010), by targeting several oncogenes 2011 EMBO Molecular Medicineincluding rat sarcoma viral oncogene homolog (RAS) (Johnson
et al, 2005). Members of the 17–92 cluster, the first oncomiR
identified (He et al, 2005), are also present in our predictor (miR-
17 andmiR-92a). Interestingly, the 17–92 cluster, which is under
the control of the myelocytomatosis viral oncogene homolog
(MYC) oncogene (He et al, 2005; O’Donnell et al, 2005), has a
role in lung development (Ventura et al, 2008) and interacts with
multiple cancer-relevant pathways (reviewed inMendell, 2008).
Finally, miR-126 and miR-486-5p have both been found to be
downregulated in primary cancer and in the sera of NSCLC
patients in several independent studies (Boeri et al, 2011; Hu et
al, 2010; Shen et al, 2011; Volinia et al, 2006; Yanaihara et al,
2006). In addition, miR-126 inhibits cancer cell growth and
metastasis in vitro and in vivo (Crawford et al, 2008; Liu et al,
2009; Tavazoie et al, 2008). In the case of miR-486-5p, while this
miRNA has not been directly mechanistically implicated in lung
cancer, it is of note that it is expressed in stem-like precursors
bronchoalveolar stem cells (BASCs) from mouse lung (Qian et
al, 2008). Thus, the potential role of our signaturemiRNAs in the
pathogenesis of NSCLC deserves further experimental attention.
While a larger study that systematically and prospectively
compares the results of LD-CT and our serum test will be needed
to optimize our blood test, we anticipate that the composition of
the 34-miRNA model will not change substantially, given its
remarkable stability. However, large-scale validation might
improve the predictive power of the test by allowing fine-tuning
of the predictive algorithm.
We envision that our serum test for NSCLC will find its main
application in the clinic as a ‘first line screening test’ for high-
risk individuals, to identify those who should undergo further
testing, including by LD-CT. Such a test might prove very useful
for high-risk population screening, as its implementation in the
clinic is cheap and minimally invasive. Furthermore, the
simplicity of the procedure avoids ‘medicalization’ of asympto-
matic individuals, which could encourage population compli-
ance to large-scale screening programmes.MATERIALS AND METHODS
Patient selection criteria
Patients with NSCLC and healthy individuals were selected from a
consecutive series of 5203 patients enrolled in the COSMOS (Veronesi
et al, 2008). All were smokers or former smokers with a smoking
exposure of more than 20 pack-years, aged over 50 (see Table 1).
Tumour stage at the time of diagnosis was determined according to
guidelines of the American Joint Committee on Cancer (http://www.
cancerstaging.org/). Informed consent was obtained from all patients.
Other cohorts of patients employed in the study are described in the
main text. A summary of the clinical and pathological information for
all patients is in Table SI of Supporting Information.
miRNA profiling and data normalization
Serum preparation and RNA extraction are described in Fig S1 of
Supporting Information. RNAs were isolated from 1ml of serum
(0.5ml for sera of the symptomatic set). MiRNA levels were analyzed
with the TaqMan1 Low Density Array microRNA Signature Panel (v1.0)EMBO Mol Med 3, 495–503 www.embomolmed.org
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The paper explained
PROBLEM:
Non-small cell lung carcinoma is the leading cause of cancer
mortality worldwide, largely due to a lack of effective tools for
early diagnosis. Patients diagnosed with early stage disease
(stage I) have a reasonably favourable prognosis (60–80%
survival at 5 years). Unfortunately, only 20–25%of all NSCLCs are
diagnosed early. Effective tools for the early detection of NSCLC,
especially in high-risk individuals (i.e. smokers), are critically
needed to reduce diagnoses of advanced stage disease (stages
III–IV) and lung cancer deaths. Several studies have reported the
usefulness of LD-CT, which is effective for the detection of
nodules (even when these are small) and which can be used to
diagnose asymptomatic lung cancers, most of which are at stage
I. There is, however, concern regarding the feasibility of large-
scale population screening by LD-CT: the technique is cumber-
some, it requires specialized health centres, and the recruitment
of at-risk individuals with no signs of disease is difficult. A blood
test, on the other hand, could be administered easily, would be
fast and cheap, would not require specialized health centres and
would encourage the recruitment of high-risk individuals for the
diagnostic anticipation of lung cancer.
RESULTS:
The authors developed a blood test for lung cancer diagnosis in
asymptomatic high-risk individuals (heavy smokers, aged over
50) based on the detection of miRNAs from serum. Sera were
collected from high-risk subjects enrolled in a large prospective
early detection trial (the COSMOS study) for lung cancer by
annual LD-CT. A diagnostic signature of 34 serum miRNAs was
identified. The signature can identify patients with early stage
NSCLC with 80% overall accuracy. In addition, the signature can
distinguish between benign lung nodules (which are a frequent
occurrence in at-risk individuals) and frank NSCLCs. Finally, the
signature can capture the time of disease onset in individual
patients over time.
IMPACT:
The authors report a blood test for the diagnosis of NSCLC of
potential impact in the design of screening programmes for early
detection in at-risk individuals, with perspective improvement in
the prognosis of the disease.(Applied Biosystems), as described in Fig S1. Data were analyzed with
SDS Relative Quantification Software version 2.2.2 (Applied Biosys-
tems). Ct values were exported into Excel software (Microsoft) for data
analysis.
According to the analyses described in Fig S1, only 147 assays (listed
in Table SII of Supporting Information) were suitable for the purpose of
our study, thus only these assays were considered for data normal-
ization and further analyses. In the training set, we selected six
miRNAs behaving as ‘housekeeping (HK) serum-miRNAs’ (miR-197,
miR-19b, miR-24, miR-146, miR-15b, miR-19a, Table SIII of Support-
ing Information) with the following criteria: (i) they passed all the
quality tests described in Fig S1, in particular, they were optimal
quantitative variables (R2¼0.99), (ii) they were expressed at high
levels and in all samples (median Ct<30; 100% of detection);
(iii) they were not statistically different among the analyzed classes
(Welch’s t-test, p>0.1); iv) they were the least variable miRNAs
among all samples (SD<0.9 Ct). Raw data were therefore normalized
by the geometric mean of the ‘housekeeping (HK) serum-miRNAs’. Only
values below a minimal threshold (Ct<36) were normalized in order
to avoid artefactual regulation due to sample normalization. Values for
the testing and symptomatic sets were normalized using the same HK
serum-miRNAs. Expression values for all serum samples used in the
study, before and after normalization, are shown in Fig S2 of
Supporting Information. In addition, to exclude the possibility that our
results were influenced by the normalization method, we repeated all
the analyses with a different method, i.e. the median normalization
method in which each sample was centred based on the median value
of all the 147 expressed miRNAs. The two different normalization
methods yielded almost identical results (R2¼0.8, p-value <0.0001;
Fig S4 of Supporting Information).www.embomolmed.org EMBO Mol Med 3, 495–503Clustering and class prediction analyses
Hierarchical clustering analysis was performed using Cluster 3.0 for
Mac OSX (http://bonsai.hgc.jp/mdehoon/software/cluster/softwar-
e.htm). Expression data were clustered using uncentred correlation
and average linkage. Tree pictures were generated using Java TreeView
software (http://jtreeview.sourceforge.net).
For class prediction, log2 median centred expression data were
analyzed using BRB-ArrayTools Version: 3.8.0-Beta_1 Release
(April 2009) (http://linus.nci.nih.govBRB-ArrayTools.html). MiRNAs sig-
nificantly different between case and control classes in the training set,
at 0.05 significance level (parametric t-test, random variance model),
were used for class prediction. The misclassification rate of the classifier
was computed by diagonal linear discriminant analysis (DLDA) and
K-fold (K¼5) cross-validation method repeated 100 times. Statistical
significance of the DLDA classifier was assessed by 1000 random
permutations of the class labels. The classification of patients in the
testing or symptomatic sets was performed blinded, using the following
prediction rule from the Diagonal linear Discriminant predictor: a
sample is classified ‘high risk’ if the inner sum of the weights (wi) (see
Table SI) and expression (xi) of the 34 miRNAs is greater than the
threshold (determined in the training set); that is, S wi xi>3.235.
To ensure that the 34 miRNA composition of our model was optimal
we repeated the entire analysis using four additional classifiers built
by using 5, 10, 15, 30 miRNAs of the initial list of 34 miRNAs (Fig S5).
Indeed, the best performance in terms of AUC was obtained by using
the 34-miRNA classifier (Fig S5).
Statistical significance of the differences of the average risk index in
the various sets of patients was calculated using ANOVA (in the case of
more than two groups) or Welch’s t-test using Prism (GraphPad
Software, Inc.). Statistical significance of the differences of the average 2011 EMBO Molecular Medicine 501
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502risk index between BDO and relative matched tumour sera was
calculated using the one-tailed paired t-test (GraphPad Software, Inc.).
Sensitivity analyses and Forest Plots were prepared using the
statistical software JMP IN (SAS), and p values calculated with the
Fisher’s exact test.Author contributions
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